‘Patient zero’ in Tennessee talks about fear, anxiety, hysteria and countless acts of kindness as the Biogen outbreak spreads

John Carroll

Editor & Founder

Chris Baumgartner updated his LinkedIn page in February to reflect his new job as vice president/East for Biogen, which followed a stint at Sage Therapeutics …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

‘Patient zero’ in Tennessee talks about fear, anxiety, hysteria and countless acts of kindness as the Biogen outbreak spreads

John Carroll

Editor & Founder

Sign up to read this article for free.

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

CMS explains what went into its first round of drug price negotiations

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

‘Pa­tient ze­ro’ in Ten­nessee talks about fear, anx­i­ety, hys­te­ria and count­less acts of kind­ness as the Bio­gen out­break spreads

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

‘Patient zero’ in Tennessee talks about fear, anxiety, hysteria and countless acts of kindness as the Biogen outbreak spreads

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

CMS explains what went into its first round of drug price negotiations

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties